RT Journal Article
SR Electronic
T1 A residual marker of cognitive reserve is associated with resting-state intrinsic functional connectivity along the Alzheimer’s disease continuum
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.17.22269026
DO 10.1101/2022.01.17.22269026
A1 Ersoezlue, Ersin
A1 Perneczky, Robert
A1 Tatò, Maia
A1 Utecht, Julia
A1 Kurz, Carolin
A1 Häckert, Jan
A1 Guersel, Selim
A1 Burow, Lena
A1 Koller, Gabriele
A1 Stöcklein, Sophia
A1 Keeser, Daniel
A1 Papazov, Boris
A1 Totzke, Marie
A1 Ballarini, Tommaso
A1 Brosseron, Frederic
A1 Buerger, Katharina
A1 Dechent, Peter
A1 Dobisch, Laura
A1 Ewers, Michael
A1 Fliessbach, Klaus
A1 Glanz, Wenzel
A1 Haynes, John Dylan
A1 Heneka, Michael T
A1 Janowitz, Daniel
A1 Kilimann, Ingo
A1 Kleineidam, Luca
A1 Laske, Christoph
A1 Maier, Franziska
A1 Munk, Matthias H
A1 Peters, Oliver
A1 Priller, Josef
A1 Ramirez, Alfredo
A1 Röske, Sandra
A1 Roy, Nina
A1 Scheffler, Klaus
A1 Schneider, Anja
A1 Schott, Björn H
A1 Spottke, Annika
A1 Spruth, Eike Jakob
A1 Teipel, Stefan
A1 Unterfeld, Chantal
A1 Wagner, Michael
A1 Wang, Xiao
A1 Wiltfang, Jens
A1 Wolfsgruber, Steffen
A1 Yakupov, Renat
A1 Düzel, Emrah
A1 Jessen, Frank
A1 Rauchmann, Boris-Stephan
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/01/19/2022.01.17.22269026.abstract
AB Background Cognitive reserve (CR) explains interindividual differences in the impact of neurodegenerative burden on cognitive and daily functioning. A residual model was proposed to estimate CR more accurately compared to static measures, such as years of education. However, the functional brain correlates of residual CR markers (CRM) remain unexplored.Methods From the DELCODE cohort, 318 participants with resting-state functional and structural MRI data were included and stratified using cerebrospinal fluid (CSF) biomarkers according to the A(myloid-β, Aβ)/T(au)/N(eurodegeneration) classification scheme, resulting in 112 Aβ-negative healthy controls and 206 Aβ-positive patients in the Alzheimer’s disease (AD) spectrum.. CRM was calculated utilizing residuals obtained from a multilinear regression model using global cognition as dependent variable and demographic and disease burden measures as predictors. Associations between the CRM and intrinsic network connectivity (INC) in resting-state networks associated with cognition were explored, including the default mode network (DMN), frontoparietal network (FPN), salience network (SAL) and dorsal attention network (DAN). Moreover, the association between memory performance-associated regional INC and CRM was assessed.Results CRM was positively associated with INC in the DMN in the entire cohort. In a subgroup analysis, the A+T+N+ group revealed an anti-correlation between SAL and DMN. Furthermore, CRM was positively associated with the anti-correlation between the memory-related regions in the FPN and the DMN in the A+ and A+T/N+ subgroups.Conclusions CRM is associated with alterations of functional connectivity in resting-state networks of cognitive function, particularly the DMN and the FPN. Our results provide evidence on individual functional network differences associated with CRM in the AD continuum.Competing Interest StatementFrank Jessen received fees for consultation from Eli Lilly, Novartis, Roche, BioGene, MSD, Piramal, Janssen and Lundbeck. Josef Priller received fees for consultation, lectures and patents from Neurimmune, Axon, Desitin and Epomedics. Robert Perneczky received speaker honoraria and fees for consultation from Janssen, Roche, Biogen, Eli Lilly, Abbott, Schwabe and Grifols.Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/29415768/ Funding StatementThe study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum fuer Neurodegenerative Erkrankungen (DZNE)), reference number BN012.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethical committees of the medical faculties of all participating sites: the ethical committees of Berlin (Charité, University Medicine), Bonn, Cologne, Goettingen, Magdeburg, Munich (Ludwig-Maximilians-University), Rostock, and Tuebingen. The process was led and coordinated by the ethical committee of the medical faculty of the University of Bonn. The registration number of the trial at the ethical committee in Bonn is 117/13.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.